og_hodl | Kalios Peptide Database

Just spoke to an HHS insider & man, Eli Lilly is going nuts with the peptide wars First of all, as we speak they are pushing the FDA to reclassify the glp-1s as biologics instead of peptides so that: 1. Compounding pharmacies can’t touch them, as they’re not allowed to dispense biologics. Only large manufacturers contracted by big pharma can produce biologics 2. They can extend the patents by 10-15 years min The FDA classifies anything under 40 amino acids a peptide, over 40 a biologic & they’re pushing extremely hard on Retatrutide Retatrutide sits at 39 amino acids, technically a peptide. But the argument they’re pushing is that certain side chains should be counted as amino acids, pushing it over the peptide threshold This strategy has precedent since pharma already used it to push fertility compounds like HCG, FSH & HMG into the biologic classification, removing them from the compounding pathway Patents expire, but the classification system doesn't

$HIMS 🚨 RFK SAYS THE FDA IS REMOVING THESE 12 PEPTIDES FROM CATEGORY 2 HERE'S WHAT THEY MIGHT COST - PER MONTH: BPC-157 - $150 - $300 Thymosin Beta-4 - $200 - $400 Epitalon - $250 - $450 GHK-Cu (injectable) - $150 - $300 MOTS-c - $250 - $500 DSIP (Emideltide) - $150 - $350 Dihexa Acetate - $200 - $450 Ibutamoren Mesylate - $150 - $325 Melanotan II - $100 - $250 KPV - $150 - $300 Semax (heptapeptide) - $150 - $250 Cathelicidin LL-37 - $300 - $600

Today, we took long-overdue action to restore science, accountability, and the rule of law. In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts Americans at risk. Now, after nominators withdrew 12 peptides, the FDA will remove them from Category 2 and will bring them to PCAC at its next two meetings, beginning in July—where independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence. • BPC-157 • Thymosin beta-4 fragment (LKKTETQ) • Epitalon • GHK-Cu (injectable) • MOTS-c • DSIP (Emideltide) • Dihexa Acetate • Ibutamoren Mesylate • Melanotan II • KPV • Semax (heptapeptide) • Cathelicidin LL-37 This action begins to restore regulated access and will immediately begin shifting demand away from the black market. We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve.